Logo image of NSTG

NANOSTRING TECHNOLOGIES INC (NSTG) Stock Fundamental Analysis

NASDAQ:NSTG - Nasdaq - US63009R1095 - Common Stock - Currency: USD

0.1053  -0.06 (-37.43%)

After market: 0.1051 0 (-0.19%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NSTG. NSTG was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of NSTG have multiple concerns. NSTG is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NSTG had negative earnings in the past year.
In the past year NSTG has reported a negative cash flow from operations.
NSTG had negative earnings in each of the past 5 years.
NSTG had a negative operating cash flow in each of the past 5 years.
NSTG Yearly Net Income VS EBIT VS OCF VS FCFNSTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

NSTG has a worse Return On Assets (-60.59%) than 91.80% of its industry peers.
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROIC N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
NSTG Yearly ROA, ROE, ROICNSTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 35.72%, NSTG is doing worse than 62.30% of the companies in the same industry.
NSTG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NSTG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
NSTG Yearly Profit, Operating, Gross MarginsNSTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

NSTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NSTG has been increased compared to 1 year ago.
The debt/assets ratio for NSTG is higher compared to a year ago.
NSTG Yearly Shares OutstandingNSTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NSTG Yearly Total Debt VS Total AssetsNSTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -5.51, we must say that NSTG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.51, NSTG is doing worse than 81.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACC2.41%
NSTG Yearly LT Debt VS Equity VS FCFNSTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

NSTG has a Current Ratio of 2.73. This indicates that NSTG is financially healthy and has no problem in meeting its short term obligations.
NSTG has a Current ratio (2.73) which is in line with its industry peers.
NSTG has a Quick Ratio of 2.02. This indicates that NSTG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.02, NSTG perfoms like the industry average, outperforming 47.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.02
NSTG Yearly Current Assets VS Current LiabilitesNSTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for NSTG have decreased strongly by -12.42% in the last year.
Looking at the last year, NSTG shows a very strong growth in Revenue. The Revenue has grown by 20.09%.
Measured over the past years, NSTG shows a small growth in Revenue. The Revenue has been growing by 2.07% on average per year.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%

3.2 Future

Based on estimates for the next years, NSTG will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.87% on average per year.
NSTG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.47% yearly.
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NSTG Yearly Revenue VS EstimatesNSTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
NSTG Yearly EPS VS EstimatesNSTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NSTG. In the last year negative earnings were reported.
Also next year NSTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSTG Price Earnings VS Forward Price EarningsNSTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSTG Per share dataNSTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

NSTG's earnings are expected to grow with 18.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.45%
EPS Next 3Y18.14%

More info and screens

0

5. Dividend

5.1 Amount

NSTG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOSTRING TECHNOLOGIES INC

NASDAQ:NSTG (2/13/2024, 9:56:56 PM)

After market: 0.1051 0 (-0.19%)

0.1053

-0.06 (-37.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2023-11-06/amc
Earnings (Next)02-27 2024-02-27/amc
Inst Owners0%
Inst Owner Change-97.01%
Ins Owners17.53%
Ins Owner Change0%
Market Cap5.07M
Analysts76.92
Price Target2.07 (1865.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.73%
Min EPS beat(2)-33.62%
Max EPS beat(2)-31.85%
EPS beat(4)0
Avg EPS beat(4)-36.24%
Min EPS beat(4)-61.05%
Max EPS beat(4)-18.46%
EPS beat(8)0
Avg EPS beat(8)-33.39%
EPS beat(12)0
Avg EPS beat(12)-25.98%
EPS beat(16)1
Avg EPS beat(16)-25.37%
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.8%
Revenue beat(4)3
Avg Revenue beat(4)1.93%
Min Revenue beat(4)-0.12%
Max Revenue beat(4)5.95%
Revenue beat(8)4
Avg Revenue beat(8)-2.76%
Revenue beat(12)7
Avg Revenue beat(12)-1.56%
Revenue beat(16)11
Avg Revenue beat(16)2.19%
PT rev (1m)0%
PT rev (3m)-78.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.82
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS3.38
BVpS-1.05
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.72%
FCFM N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
F-Score2
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.24%
Cap/Sales 12.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.02
Altman-Z -5.51
F-Score2
WACC2.41%
ROIC/WACCN/A
Cap/Depr(3y)187.15%
Cap/Depr(5y)166.43%
Cap/Sales(3y)10.15%
Cap/Sales(5y)8.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%
EBIT growth 1Y-18.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.66%
EBIT Next 3Y23.81%
EBIT Next 5Y19.06%
FCF growth 1Y-50.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.03%
OCF growth 3YN/A
OCF growth 5YN/A